Morepen Logo

"EDQM awards Certificate of Suitability (CEP) to Morepen for Montelukast Sodium & Atorvastatin Calcium Trihydrate. Morepen already holds CEP for Loratadine"       "Morepen Laboratories scores No.1 position globally for its bulk drug Montelukast"      "Company's efficient operations result in over 25-fold increase in net profit for the FY 2015-16"     

About The Company

Some things will always remain unfettered. Like sunshine and air, like suffering and joy, like sharing and caring. Some things will never recognize the confines of space and time. Like human endeavour and enterprise, like the desire to touch life. At Morepen, we are taking our expertise and experience in Wellness to new countries and new people with an increasing focus on global exports. And in doing so, our spirit of caring is crossing boundaries.

Read more

Active Pharmaceutical Ingredient

Morepen started its bulk drug business in 1985 with the manufacturing of Ampicillin, Amoxicillin...

Read more

Formulations

Since our inception in 1995, the Medicus division has been catering to the needs of the common man...

Read more

HomeHealth

Recognizing the requirement of innovative and technologically advanced ...

Read more

Dr. Morepen

Keeping in line with Morepen's commitment to healthier future for all, The company has taken...

Read more

Grooming

Dr. Morepen, now introduces in India, GUBB USA. GUBB international grooming range is specially designed to recharge you & brighten you..

Read more

Wellness

Dr. Morepen NOW is a Heart Health Centre, with a 360 ° approach towards the treatment of heart patients & people with related diseases like diabetes, high blood pressure, cholesterol and obesity. Here, your heart fitness is their top priority...

Read more

Recent News

February - 8 - 2017
Morepen Labs reports yet another growth-filled quarter-Company’s topline goes up by 23 per cent, backed by a 74% jump in the sales of its bulk drug Montelukast in the Q3 of fiscal 2016-17
new

 

February - 8 - 2017
Un-audited Financial Results For the Quarter/Nine-months ended 31st December, 2016
new

 

November - 9 - 2016
Morepen Labs reports 118 percent jump in Net Profits for the Q2 of FY 2016-17
new

 

November - 9 - 2016
Un-audited Financial Results For the Quarter/Half-year ended 30th September, 2016
new

 

August - 25 - 2016
Annual Report 2015-16

 

August - 25 - 2016
Notice of AGM 2015-16

 

August - 09 - 2016
Un-audited Financial Results For the Quarter ended 30th June 2016

 

May - 10 - 2016
Audited Financial Results For the Quarter and Year ended 31st March 2016

 

May - 10 - 2016
Morepen Laboratories scores No.1 position globally for its bulk drug Montelukast

 

February - 08 - 2016
Unaudited Financial Results and Limited Review Report for the Quarter ended 31st December, 2015

 

November - 04 - 2015
Unaudited Financial Results for the Quarter ended 30th September, 2015.

 

September - 21 - 2015
Scrutinizers Report for the AGM - 18.09.2015.

 

August- 21 - 2015
Notice of AGM 2014-15

 

August- 21 - 2015
Annual Report 2014-15

 

August- 7 - 2015
Unaudited Financial Results for the Quarter ended 30th June, 2015

 

May- 15 - 2015
Audited Financial Results for the Quarter and Year ended 31st March, 2015

 

Feb- 11 - 2015
Unaudited Financial Results for the Quarter ended 31st December, 2014

 

Nov- 13 - 2014
Unaudited Financial Results for the Quarter ended 30th September, 2014

 

 

 

 


View all news

 

 

 

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player